{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:40:13Z","timestamp":1791200413261,"version":"4.2.0"},"reference-count":105,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,3,16]],"date-time":"2009-03-16T00:00:00Z","timestamp":1237161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The mammalian target of rapamycin (mTOR) is a serine\/threonine kinase that functions as a key regulator of cell growth, protein synthesis, and cell\u2010cycle progression through interactions with a number of signalling pathways, including PI3K\/AKT, ras, TCL1, and BCR\/ABL. Many haematological malignancies have aberrant activation of the mTOR and related signalling pathways. Accordingly, mTOR inhibitors, a class of signal transduction inhibitors that were originally developed as immunosuppressive agents, are being investigated in preclinical models and clinical trials for a number of haematological malignancies. Sirolimus and second\u2010generation mTOR inhibitors, such as temsirolimus and everolimus, are safe and relatively well\u2010tolerated, making them potentially attractive as single agents or in combination with conventional cytotoxics and other targeted therapies. Promising early clinical data suggests activity of mTOR inhibitors in a number of haematological diseases, including acute lymphoblastic leukaemia, chronic myeloid leukaemia, mantle cell lymphoma, anaplastic large cell lymphoma, and lymphoproliferative disorders. This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2009.07657.x","type":"journal-article","created":{"date-parts":[[2009,3,16]],"date-time":"2009-03-16T08:38:58Z","timestamp":1237192738000},"page":"569-580","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies"],"prefix":"10.1111","volume":"145","author":[{"given":"David T.","family":"Teachey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie I.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23580"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207698"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-0929"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800908786733513"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2007.03.020"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(05)70272-8"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2008.00655.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706061"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2436348100"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4704"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-008-8038-9"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00637.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.078808"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00256-8"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701809214"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V110.11.856.856","article-title":"The mTOR inhibitor RAD001 (Everolimus) improves survival in preclinical models of primary human ALL","volume":"110","author":"Crazzolara R.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0189"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0582-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60456-0"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666040-00009"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1725"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700494"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90136-E"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2062"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4409"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1331"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1153"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M309999200"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986708786848578"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.204"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.02.009"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404471"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2004.11.003"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.004"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3434"},{"key":"e_1_2_8_38_1","first-page":"1433","article-title":"Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells","volume":"90","author":"Hipp S.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.07.023"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21296"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.2.3.360"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0071"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1494"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4513"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2193"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33337"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0849"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-085092"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-137737"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02899918"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2911"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.s.009"},{"key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood.V108.11.161.161","article-title":"A phase 1 dose escalation study of the mTOR inhibitor sirolimus and MEC chemotherapy targeting signal transduction in leukemic stem cells for acute myeloid leukemia","volume":"108","author":"Luger S.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_55_1","first-page":"5716","article-title":"Bcr\u2010Abl kinase modulates the translation regulators ribosomal protein S6 and 4E\u2010BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly C.","year":"2003","journal-title":"Cancer Research"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000063934.89714.19"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1052"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-1973fje"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191379498"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400063101"},{"key":"e_1_2_8_61_1","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN\u2010deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat M.S.","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.243"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404980"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.144"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm088"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205923"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.051078"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-007-0043-z"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22881"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00140-3"},{"key":"e_1_2_8_71_1","first-page":"28","article-title":"Sirolimus (SRL)\u2010Based GVHD Prophylaxis after TBI\/TT\/Cy Allogeneic HSCT in Pediatric Patients with HR ALL: Results of a Multi\u2010Insitutional Pilot Study","volume":"14","author":"Pulsipher M.","year":"2008","journal-title":"O Biologico"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2281"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307081401"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.4.11.2159"},{"key":"e_1_2_8_75_1","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V110.11.2834.2834","article-title":"A phase I trial of sirolimus (rapamycin) in pediatric patients with relapsed\/refractory leukemia","volume":"110","author":"Rheingold S.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0539"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400005353"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1372"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn192"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015586"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150250"},{"key":"e_1_2_8_82_1","unstructured":"Saydam G. H C. P C. Bertino J.R.&Erickan\u2010Abali E.(2005)mTOR inhibition leads to increased sensitivity to methotrexate.AACR 98th Annual Meeting. Abstract No. 3303."},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00117-3"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.001"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04869"},{"key":"e_1_2_8_86_1","first-page":"5027","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI\u2010779","volume":"62","author":"Shi Y.","year":"2002","journal-title":"Cancer Research"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01892.x"},{"key":"e_1_2_8_88_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8514","article-title":"Activity of single agent temsirolimus (CCI\u2010779) in non\u2010mantle cell non\u2010Hodgkin lymphoma subtypes","volume":"26","author":"Smith M.S.","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1935"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-010124"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-137141"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07595.x"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90034-9"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3018"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06210.x"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.09.006"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.016"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3429"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4468"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403968"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2447"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP58077"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0764"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.4161\/auto.6232"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3426"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6163"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2009.07657.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2009.07657.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:43:45Z","timestamp":1695919425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2009.07657.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,11]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1365-2141.2009.07657.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07657.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,11]]},"assertion":[{"value":"2009-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}